Table 2.
Baseline DSA and Crossmatch Testing
| Variable | Eculizumab-Treated +XM Patients (n=30) | +XM Control Patients (n=48) | P Value Eculizumab vs +XM Control Patients |
|---|---|---|---|
| Baseline B-cell flow cytometric crossmatch, mean (SD) | 306 (92) | 323 (78) | .35 |
| Class I DSA only, No. (%) | 11 (36.7) | 19 (39.5) | |
| Class II DSA only, No. (%) | 9 (30.0) | 12 (25.0) | |
| Both class I + II DSA, No. (%) | 10 (33.3) | 17 (35.4) | .89 |
| Anti-A specificity, No. (%) | 17 (56.7) | 24 (50.0) | .57 |
| Anti-B specificity, No. (%) | 17 (56.7) | 20 (41.7) | .20 |
| Anti-DR specificity, No. (%) | 13 (43.3) | 18 (37.5) | .61 |
| Anti-DQ specificity, No. (%) | 12 (40.0) | 20 (41.7) | .88 |
| Sum class I DSA MFI, mean (SD) | 4,193.3 (4,889.0) | 4,556.68 (5,083.0) | .76 |
| Sum class II DSA MFI, mean (SD) | 4,037.07 (5,183.3) | 3,128 (4,141.2) | .40 |
| Sum of class I and class II DSA MFI, mean (SD) | 11,905.0 (8,985.3) | 9,592.5 (7,806.2) | .24 |
| Number of DSA per patient, mean (SD) | 2.2 (1.0) | 2.6 (1.4) | 0.12 |
| Pretransplant plasmapheresis, No. (%) | 17 (56.7) | 32 (66.7) | .52 |
| Number of pretransplant plasmapheresis treatments, mean (SD) | 4.6 (1.3) | 4.4 (1.4) | .78 |
| IgG3+ (n=15), No. (%) | 8 (53.3) | NA | |
| C1q+ (n=18), No. (%) | 14 (77.8) | NA |
Abbreviations: DSA, donor-specific antibody; IgG, immunoglobulin G; MFI, mean fluorescence intensity; NA, not applicable; −XM, negative crossmatch; +XM, positive crossmatch.